Researchers at the University of Kansas Medical Center are studying two knee injections, Zilretta and Kenalog, that are approved by the FDA to reduce knee osteoarthritis pain. This study looks at how each injection affects blood glucose (blood sugar) levels in adults with type 2 diabetes and painful knee osteoarthritis.

You may be eligible for this study if you meet the following criteria.

Inclusion Criteria:

• Adults ages 40+
• Diagnosed with type 2 diabetes for at least 1 year
• Currently taking a stable dose of anti-diabetic medication (including insulin) for at least 1 month
• History of knee osteoarthritis, with knee pain on most days of the past month
• Live within driving distance of Kansas City, KS/MO (about 50-60 miles, including Lawrence, Olathe, Overland Park and Roeland Park)

Exclusion Criteria:

• Reactive, rheumatoid, or psoriatic arthritis
• Hardware (such as an implant) in the knee being treated
• Active cancer, or cancer within the last 3 years (certain skin and cervical cancers accepted)
• History of HIV, hepatitis B, or hepatitis C

Including phone calls and follow-up visits, your total participation will last about three months after the knee injection.

Study Visits

• A screening visit to review your medical history and medications, with blood work and surveys about knee pain and diabetes symptoms
• Wear a continuous glucose monitor (CGM) for 7-10 days before treatment
• On treatment day, a timed walking and stair-climbing test, then a single injection in your most painful knee (either Kenalog or Zilretta, chosen at random)
• You will be given a second CGM on treatment day to measure post-treatment glucose levels
• Check-in phone calls for three days after the injection, plus two brief surveys
• Three in-office visits at Days 15, 43, and 85 to complete surveys and physical function tests

Participants may receive $230, or $405 if assigned to the salivary testing group.

There is no cost for you to participate in our research study.